BioAtla Reports Third Quarter 2022 Financial Results and Highlights Recent ProgressGlobeNewsWire • 11/03/22
BioAtla to Announce Third Quarter 2022 Financial Results and Provide Business Highlights on November 3, 2022GlobeNewsWire • 10/27/22
Himalaya Therapeutics Announces Interim Phase 2 Results for Mecbotamab vedotin (HTBA3011)PRNewsWire • 09/12/22
BioAtla, Inc. (BCAB) CEO Jay Short on Q2 2022 Results - Earnings Call TranscriptSeeking Alpha • 08/13/22
BioAtla Reports Second Quarter 2022 Financial Results And Highlights Recent ProgressGlobeNewsWire • 08/09/22
BioAtla to Announce Second Quarter 2022 Financial Results and Provide Business Highlights on August 9, 2022GlobeNewsWire • 08/02/22
BioAtla, Inc. (BCAB) CEO Jay Short on Q1 2022 Results - Earnings Call TranscriptSeeking Alpha • 05/07/22
BioAtla Reports First Quarter 2022 Financial Results and Highlights Recent ProgressGlobeNewsWire • 05/04/22
BioAtla to Announce First Quarter 2022 Financial Results and Provide Business Highlights on May 4, 2022GlobeNewsWire • 04/08/22
BioAtla Announces Clinical Collaboration with Bristol Myers Squibb to Study Mecbotamab Vedotin (BA3011) and Ozuriftamab Vedotin (BA3021) in Combination with Opdivo® (nivolumab) for Treatment of Solid TumorsPRNewsWire • 01/10/22
BioAtla Announces Third Quarter 2021 Financial Results And Provides Clinical And Business UpdatePRNewsWire • 11/15/21
BioAtla Announces Second Quarter 2021 Financial Results And Provides Clinical UpdatePRNewsWire • 08/13/21
BioAtla Announces First Quarter 2021 Financial Results And Provides Business UpdatePRNewsWire • 05/12/21